Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Slides:

Advertisements

Similar presentations

Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail by James Pettitt, Larry Zeitlin, Do H.

Advertisements

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 1. Schematic representation of the MANO method.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

MRSA virulence proteins cause LMC death and diminished CLV function

Fig. 1 MT-2 ameliorates asthmatic pulmonary resistance.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 1 DMF promotes viral infection.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Fig. 3 TLR8 signaling induces CXCL4 and IFN-α secretion by SSc PDCs.

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 1. IS mediates a hyperthrombotic uremic phenotype in an AHR-dependent manner across CKD stages. IS mediates a hyperthrombotic uremic phenotype in.

Fig. 3 Biological function of TG2 and the interaction with MT-2.

Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 6. Epitope mapping of C12G6.

Fig. 4. MATE1 transcription in RCC.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 4 Phylogeny of rabies strains isolated during and after the mass vaccination campaign. Phylogeny of rabies strains isolated during and after the mass.

Fig. 4. Expression of HGF in liver ECs cooperates with NOX4 inhibition to enhance engraftment of regenerative hepatocytes. Expression of HGF in liver ECs.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 7. ApoMSCs exert immunosuppressive activity in GvHD and elicit IDO in engulfing recipient phagocytes. ApoMSCs exert immunosuppressive activity in.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 1. In vitro binding and neutralization activities of C12G6.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 2 Adoptive transfer of adult Ox40−/− splenocytes into adult HBVEnvRag−/− mice alters hepatic inflammation, HBsAg clearance, HBsAb seroconversion,

Fig. 1 Collecting popliteal lymphatic vessels exhibit diminished contraction and lymph velocity after MRSA infection. Collecting popliteal lymphatic vessels.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 4 Spinally grafted iPSC-NPCs show long-term survival and neuronal and glial differentiation in syngeneic recipient in the absence of immunosuppression.

Vaccination induces activation of cTFH cells and transient ASCs

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 3 Activation of freshly isolated CD4+ T cells from HIV-infected patients on ART selectively reverses baseline blocks to splicing, elongation, and.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 5. Rises in RSV PRNT during the surveillance period.

KIF13A depletion leads to a drop in virus titers, without affecting viral protein expression. KIF13A depletion leadsto a drop in virus titers, without.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses by Chenguang Shen, Junyu Chen, Rui.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Presentation transcript:

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets. Prophylactic and therapeutic efficacy of C12G6 in ferrets. (A to D) Virus titers in nasal washes from ferrets treated with C12G6 (20 mg/kg) or control antibody (C5G6) 1 day before (prophylactic groups) or after (therapeutic groups) intranasal infection with 1 × 107 TCID50 of B/Florida/4/2006 (A and B) or B/Brisbane/60/2008 (C and D). (E to H) Changes in body temperatures of ferrets treated with C12G6 (20 mg/kg) or control antibody (C5G6) 1 day before (prophylactic groups) or after (therapeutic groups) intranasal infection with 1 × 107 TCID50 of B/Florida/4/2006 (E and F) or B/Brisbane/60/2008 (G and H). Nasal washes were collected on the indicated days and titrated by TCID50 assay. Body temperatures are expressed as the percentage of baseline values. The black bars indicate mean values. Statistical analysis was performed by t test. *P < 0.05, compared to the control IgG–treated group. Chenguang Shen et al., Sci Transl Med 2017;9:eaam5752 Published by AAAS